Company profile
BeyondSpring Inc.
NASDAQ:BYSIBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PLINABULIN | phase3 | — | 6 | completed, not_yet_recruiting, unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02504489 | phase3 | completed | 2015-12-01 | 2021-07-21 | BeyondSpring Pharmaceuticals Inc. | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC |
| NCT07361484 | phase3 | not_yet_recruiting | 2026-06-01 | 2029-06-01 | BeyondSpring Pharmaceuticals Inc. | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) |
| NCT04227990 | phase2 | completed | 2017-11-27 | 2018-10-15 | BeyondSpring Pharmaceuticals Inc. | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia |
| NCT04345900 | phase2 | completed | 2017-04-05 | 2018-03-20 | BeyondSpring Pharmaceuticals Inc. | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 |
| NCT03102606 | phase3 | completed | 2018-05-29 | 2018-12-12 | BeyondSpring Pharmaceuticals Inc. | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 |
FDA applications (0)
No records yet.